NUVB

NUVB just crossed from clinical-stage hope to commercial reality: IBTROZI (taletrectinib) won FDA approval on June 11, 2025 for ROS1+ NSCLC and launched in the U.S. that month, with the same asset already approved in Japan (via NK) and China (via Innovent, branded DOVBLERON). FY2025 revenue of $62.9M, up 699% off a $7.87M base, is the first hard evidence the launch is taking hold, and the January 2026 Eisai license for Europe is third-party validation that the asset has global value. The team is the real edge here — founder/CEO David Hung previously built Medivation around Xtandi and sold it to Pfizer for $14.3B, so this is not a first-time management group guessing at oncology commercialization.

The balance sheet is sturdier than the headline $164M cash suggests. Current assets of $572M against just $82.2M current liabilities (a ~7x current ratio) imply roughly $400M of additional liquid investments beyond cash, and total liabilities of $289M sit just below $306M of equity (0.95x). That liquidity cushions the cash burn — operating cash flow was -$173M and the net loss was -$205M — and pushes the dilution clock out a couple of years rather than months. Long-term debt is modest at $47.2M. So this is not a balance-sheet-stress 'avoid'; it is a funded, revenue-generating commercial launch.